
iGlarLixi improves glycemic control without weight gain or increased hypoglycemia over 24 weeks. 162 participants switched from premixed insulin (89.5% from twice-daily). HbA1c dropped by 1.2%, with 37.6% reaching <7%. Body weight decreased by 1.0 kg, and fasting/post-prandial glucose improved significantly. 38.3% of participants experienced confirmed symptomatic hypoglycemia. This treatment effectively manages glucose with minimal adverse effects.
Like
Save
Share